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Abstract
Introduction We aimed to quantify health outcomes and
programmatic implications of scaling up cervical cancer
(CC) screening and treatment options for women living
with HIV in care aged 18–65 in Kenya.
Methods Mathematical model comparing from 2020
to 2040: (1) visual inspection with acetic acid (VIA) and
cryotherapy (Cryo); (2) VIA and Cryo or loop excision
electrical procedure (LEEP), as indicated; (3) human
papillomavirus (HPV)-DNA testing and Cryo or LEEP; and
(4) enhanced screening technologies (either same-day
HPV-DNA testing or digitally enhanced VIA) and Cryo or
LEEP. Outcomes measured were annual number of CC
cases, deaths, screening and treatment interventions, and
engaged in care (numbers screened, treated and cured)
and five yearly age-standardised incidence.
Results All options will reduce CC cases and deaths
compared with no scale-up. Options 1–3 will perform
similarly, averting approximately 28 000 (33%) CC cases
and 7700 (27%) deaths. That is, VIA screening would
yield minimal losses to follow-up (LTFU). Conversely,
LTFU associated with HPV-DNA testing will yield a lower
care engagement, despite better diagnostic performance.
In contrast, option 4 would maximise health outcomes,
averting 43 200 (50%) CC cases and 11 800 (40%) deaths,
given greater care engagement. Yearly rescreening with
either option will impose a substantial burden on the health
system, which could be reduced by spacing out frequency
to three yearly without undermining health gains.
Conclusions Beyond the specific choice of technologies
to scale up, efficiently using available options will drive
programmatic success. Addressing practical constraints
around diagnostics’ performance and LTFU will be key to
effectively avert CC cases and deaths.

Introduction
Cervical cancer (CC) remains a major cause
of cancer-
related morbidity and mortality
among women globally, despite being largely
preventable.1 Sub-Saharan Africa (SSA) has
the highest CC incidence for a region in
the world, likely due to both low coverage of

Key questions
What is already known?
►► Cervical cancer (CC) screening and treatment strat-

egies have been shown to be cost-effective and
life-saving.
►► Modelling studies to date have focused on the cost-
effectiveness of CC screening and treatment options
in hypothetical cohorts.

What are the new findings?
►► This is the first study to evaluate the potential

population-level impact of CC screening and treatment interventions among women living with HIV
(WHIV) in care by recreating the entire population of
interest, including their demographic structure, their
age and HIV-specific risk of human papillomavirus
(HPV) disease progression and antiretroviral therapy
initiation currently and over time.
►► Also for the first time, this study assesses the scale-
up of a country’s CC screening and treatment guidelines and identifies how intervention factors (eg,
diagnostic performance, losses to follow-
up) will
affect programmatic success.

What do the new findings imply?
►► Maximising health outcomes among WHIV in care in

Kenya will rely more on the efficient use of available
resources than on specific CC screening and treatment technologies.
►► A successful scale-up of HPV-DNA tests will require
concerted efforts to minimise losses to follow-up
(eg, single-
visit, test-
and-
treat approach), while
scaling up visual inspection methods will demand
continuous provider training and technological improvements (eg, digitally enhanced imaging) to maximise its diagnostic performance.

preventative services and high prevalence of
HIV.1 2 HIV is thought to increase the risk of
acquiring cervical infection with human papillomavirus (HPV) and developing cancerous
lesions.3 4
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Methods
Mathematical model
We adapted an existing individual-based model coded
in C++ to represent the entire Kenyan population from
1950 to 2035. The model design and mechanism has been
described previously.11 12 The model runs in continuous
time and simulates births, deaths, HIV infection, disease
progression and treatment. Demographic events (eg, age
composition in 1950, births and deaths) were assigned
probabilistically, based on age-
specific fertility and
age and sex-specific mortality rates for Kenya from the
United Nations World Population Prospects (UNWPP),
accounting for changes over time (online supplementary
figure S2).13 HIV-related events (eg, age and sex-specific
HIV incidence, including paediatric infections), and
access to ART, accounting for historic changes in CD4
eligibility, were simulated based on data from the Joint
United Nations Programme (UNAIDS) for Kenya.14
CD4 count at seroconversion, disease progression and
mortality were based on modelling estimates for SSA
(online supplementary figure S3).15 Although individual-
level ART adherence and failure were not explicitly
modelled, the model recreated trends of ART coverage
by age, sex and CD4 count at ART initiation over time.14
A validated natural history model of HPV infection and
progression through mutually exclusive stages of related
cervical disease was used.16 For the case of females aged
15–65, events of cervical infection with HPV were assigned
probabilistically, accounting for age and HIV-
specific
2

risk (figure 1). On infection with HPV, individuals progress through the mutually exclusive stages of cervical
intraepithelial neoplasia (CIN) grade 1, CIN grade 2/3,
carcinoma in situ and CC, or experience spontaneous
recovery from HPV infection, CIN 1 or CIN 2/3.16 Transition through disease stages or spontaneous recovery
was modelled probabilistically, also accounting for individuals’ age and HIV-related risk (online supplementary
table S1).16 Individuals who recover from cervical disease
were at risk of new infection events, assuming no gained
immunity.16
The model makes four key assumptions about cervical
disease progression among WHIV compared with HIV-
negative women (figure 1A—red annotations, and online
supplementary table S1):
4
►► Higher risk of HPV infection.
4
►► Lower probability of recovering from HPV infection.
3
►► Higher risk of progression from HPV to CIN stages.
►► WHIV on ART for 2 years or more were assumed to
have the same natural history as HIV-negative women.
HPV disease progression was modelled independent
of CD4 count. Instead, duration on ART (≥2 years) was
assumed to be a proxy of immunological reconstitution
and, therefore, reduce the risk of cervical disease states,
in line with recent robust evidence comparing time on
ART for longer than 2 years to no or shorter term use.17
Model parameters (online supplementary table S1 and
figure S1) were drawn from the literature, where available,
or calibrated by exploring plausible ranges and fitting
simultaneously to available Kenyan epidemiological data
(online supplementary table S2).16 Epidemiological
data were collated through an original systematic review
and meta-analysis of age and HIV-specific prevalence of
composite HPV (ie, any genotype) and of CIN 2/3, age-
specific CC incidence and standardised incidence rate of
CC among WHIV compared with HIV-negative women,
as described in a recent publication from our group.16
Briefly, we adhered to Preferred Reporting Items for
Systematic Reviews and Meta-Analyses and Meta-analyses
of Observational Studies in Epidemiology recommendations for systematic reviews and meta-analyses,18 19 and
searched Embase, Medline and the Cochrane Library,
from inception to 30 May 2018, as well as grey literature.
Data on the cervical disease outcomes of interest were
pooled in a meta-analysis with random effects model.16
Outcomes from the meta-analysis were used as calibration targets for the model parameters (online supplementary material - figure S4).
Scale-up of CC screening and treatment care options
From 2020 to 2040, the model compared the scale-up
of the following four options to 70% coverage of WHIV
in care (ie, WHIV on ART) aged between 18 and 65
(figure 1B and table 1):
1. VIA-Cryo only: screening with VIA and, for those with
a positive test, treatment with Cryo on the same visit in
a pragmatic way (ie, regardless of Cryo eligible or not,
assuming they were the only technologies available).
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The WHO recently issued a call to eliminate CC.5
They advise countries to aim for at least 70% coverage
with CC screening and treatment services, in order to
achieve population-level health gains, with women living
with HIV (WHIV) signalled as a key target population.5 6
Kenyan guidelines recommend screening WHIV for CC
at HIV diagnosis and yearly thereafter.6 For WHIV, HPV-
DNA tests are the screening method of choice, with pragmatic approaches like visual inspection with acetic acid
(VIA) as an alternative.7 Recommended treatments for
precancerous lesions include cryotherapy (Cryo) and
loop excision electrical procedure (LEEP).6 However,
a recent national survey indicated that only 16.4% of
eligible women, regardless of HIV status, had ever been
screened for CC.8 Practical challenges to achieving
screening targets include overall low acceptability of CC
screening, high loss to follow-up (LTFU) rates, and infrastructure and commodity constraints.9 10
We aim to quantify potential population-level health
benefits of scaling up CC screening and treatment services
among WHIV in care (ie, those on antiretroviral therapy
(ART)) in the coming two decades and compare diagnostic and treatment options recommended by Kenyan
guidelines to identify factors that could affect programmatic success. This analysis aims to support ongoing
policy and implementation discussions in Kenya and the
wider SSA region.

BMJ Global Health

2. VIA-Cryo plus LEEP: where, added to the above, LEEP
was available for individuals with Cryo-ineligible lesions (assuming the need for referral to a specialised
clinic).
3. HPV-DNA-Cryo plus LEEP: screening with HPV-DNA
testing, which was assumed to require two visits (ie,
one for testing and another to collect results) and
treatment with either Cryo or LEEP. For HPV-DNA-
positive women, Cryo was performed at collection of
results or, if ineligible, LEEP on referral to a specialised clinic.
4. Enhanced technologies: where testing was assumed
to be done with either same-
day HPV-
DNA testing
or digitally enhanced VIA (ie, use of digital imaging
devices to visualise VIA-stained cervix and increase its

sensitivity to that of HPV-DNA testing). Treatment was
performed with either Cryo during the same visit or
LEEP on referral, given Cryo eligibility.
Options were modelled individually as a uniform
(national-
level) two-
phase process scale-
up strategy,
to allow for comparisons. Phase I, from 2020 to 2022,
consisted of a first delivery of the option to 70% of age-
eligible WHIV in care. During phase II, from 2023 to
2040, delivery was scaled up to target 70% of age-eligible
WHIV in care annually, including WHIV who newly
started ART. The sensitivity and specificity of screening
tests and the efficacy of treatment options replicated
reported parameters from recent Kenyan studies among
WHIV in care (table 1). Also, rates of individuals refusing
CC screening services and LTFU reflect those observed
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Figure 1 (A) HPV natural history model and (B) outline of the options of care evaluated for scale-up. (A) Transition probabilities
and rates vary by age and HIV status, as shown in blue and red annotations, respectively. Spontaneous recovery is possible
from HPV and CIN stages. (B) Losses to follow-up (LTFU) are shown in red and occur when another visit to a health facility
is necessary (ie, during HPV-DNA testing and from screening to LEEP). For definition and values of model parameters, see
table 1. *Represents screening with either digitally enhanced VIA or same-day HPV-DNA. **Rescreening carried out yearly from
2023 onwards (phase II), with pool of age-eligible WHIV in care being sampled each year at random for 70% coverage. ART,
antiretroviral therapy; CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; Cryo, cryotherapy;
HPV, human papillomavirus; LEEP, loop excision electrical procedure; LTFU, loss to follow-up; VIA, visual inspection with acetic
acid; WHIV, women living with HIV.
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Diagnostic performance
VIA
Sensitivity
Specificity

Description

Value (%)

Values specific for detection of CIN 2+ lesions among
WHIV in Kenya, irrespective of age or stage of cervical
abnormality.

Reference
28

62.70
65.90

HPV-DNA
Sensitivity

83.60

Specificity

55.70

Treatment efficacy
Cryo (eligible lesions)*

Values specific to WHIV in Kenya, irrespective of age or
stage of cervical abnormality.

70

20

Cryo (ineligible lesions)*

Efficacy was defined as the probability of remaining
cervical disease free at 24 months after treatment.

35

Assumed

LEEP (Cryo ineligible)*

For Cryo-ineligible lesions, the model assumed efficacy
of Cryo to be half, in absence of empirical data.

80.20

21

0
CIN 1 and CIS values were assumed. CIN 2/3 value from
an implementation study from the Zambia, specifically
16.70
using VIA without digital enhancement or other means for
100
increased sensitivity.

43

Averaged value from two Kenyan surveys, one of which
specifically included diagnosed WHIV in its sample.

13

22 23

Testing with HPV-DNA assumed to require two clinic
visits (one for testing and one to obtaining results).
Treatment with LEEP assumed to require referral to a
specialised clinic.

25

9 10

Proportion of Cryo-ineligible* lesions
CIN 1
CIN 2/3
CIS
Individuals refusing CC services
LTFU
From testing with HPV-DNA to
obtaining of results
From obtaining results (either with VIA
or HPV-DNA) to treatment with LEEP

49

*The model assumed that 16.7% of individuals with CIN 2/3 status and that all with CIS and CC status had signs of Cryo ineligibility. Per
clinical practice guidelines, Cryo-eligible lesions are those that do not have signs of invasive cancer (eg, bleeding), that are visible in their
entirety, that do not extend more than 2–3 mm into the endocervical canal (which should be normal in appearance) and that can be fully
covered by the Cryo probe.
CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; Cryo, cryotherapy; HPV, human papillomavirus; LEEP, loop
excision electrical procedure; LTFU, loss to follow-up; VIA, visual inspection with acetic acid; WHIV, women living with HIV.

in programmatic evaluations within HIV care facilities
in Kenya.9 10 20–23 Individuals for whom treatment was
effective and who recovered were assumed to remain
cervical disease free for 24 months and, as above, go
back to susceptible thereafter and be at risk of new HPV
infections accounting for their age and ART status. The
model assumed individuals’ LTFU during a specific year
remained eligible for screening and treatment on subsequent years, as long as they remained within age eligibility. For simplicity, no modes of differentiated care (eg,
offering LEEP for those recurring with cervical disease
regardless of their cervical status) were simulated. Also,
the present modelling analyses do not consider any
scale-
up in screening and treatment activities among
HIV-negative women.
For each option, we quantified the following outcomes:
►► Number of incident CC cases and CC deaths.
►► Age-standardised incidence of CC by 5-year periods
(eg, 2020–2024, and so on), using the WHO population and standardisation method.24
4

Care engagement, including numbers screened,
treated and cured.
►► Number of screening tests performed, treatment
administered and LTFU.
Outcomes were compared with a scenario with no
scale-
up in CC screening and treatment, henceforth
referred to as status quo. Forward projections assumed
a UNWPP medium variant in fertility and mortality,
that HIV incidence remained stable at 2017 levels, that
ART coverage reached UNAIDS 90:90:90 targets by
2020 and remained stable thereafter. All results were
based on an average of 100 model runs. Sensitivity analyses were performed to account for uncertainty around
target coverage, LTFU probabilities and frequency of
rescreening, HIV incidence and ART coverage (online
supplementary material).
To ensure transparency and reproducibility of our
modelling analyses, we adhered to standardised guidelines for reporting of agent-based simulation studies, as
further discussed in the online supplementary material
►►
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Table 1 Parameters for CC screening and treatment options
Parameter

BMJ Global Health

Patient and public involvement
No patients or members of the public were involved in
the design or carry-out of the present study.
Results
Burden of HPV-related cervical disease under status quo
The model estimates that the population of WHIV in
care in Kenya will increase from 0.91 million in 2020 to
1.73 million in 2040, with their mean age rising from 37.5
in 2020 to 44.1 in 2040. This will be driven by the effect
of ART on extending their life expectancy. In the same
period, the prevalence of HPV and CIN 2/3 is predicted
to decrease from 55.8% and 7.6%, respectively, in 2020
to 47.7% and 4.0%, respectively, in 2040. This decrease
by 8.1% in HPV prevalence and by 3.6% in CIN 2/3 prevalence will mainly be driven by the protective effect of

ART against HPV infection and progression to CIN 2/3.
In the hypothetical absence of ART only a 3.6% and 0.8%
reduction in HPV and CIN 2/3 prevalence, respectively,
would be observed over the 20-year period, driven by a
younger population of WHIV with a higher mortality,
similar to the pre-ART era.
The above reduction in cervical HPV infection and
precancerous lesions will result on an overall decrease
in the age-
standardised incidence of CC among
WHIV from 241 per 100 000 women-years in 2020–
2024 to 218 per 100 000 women-y ears in 2035–2039
(figure 2C). However, the predicted growth in population numbers will drive a rise in the yearly number
of incident CC cases and deaths among WHIV in care
(). These will reach a cumulative total of 86 115 CC
cases and 44 742 CC-r elated deaths between 2020 and
2040 (figure 2A,B and supplementary material table
S3).

Figure 2 Predicted health outcomes of scaling up different options of cervical cancer (CC) screening and treatment. (A)
Cumulative incident CC cases, (B) cumulative CC-related deaths, and (C) age-standardised incidence of CC per 100 000
person-years. Cryo, cryotherapy; HPV, human papillomavirus; ICC, invasive cervical cancer; LEEP, loop excision electrical
procedure; LTFU, loss to follow-up; VIA, visual inspection with acetic acid.
Perez-Guzman PN, et al. BMJ Global Health 2020;5:e001886. doi:10.1136/bmjgh-2019-001886
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- table S7.25 All modelling estimates refer solely to the
simulated population of WHIV in care.
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Figure 3 Predicted impact on the health system of scaling
up cervical cancer (CC) screening and treatment options. (A)
Percentage of CC cases averted (vs status quo) according
to sensitivity and losses to follow-up of screening tests. (B)
Care engagement. Treated refers to women who receive
either Cryo or loop excision electrical procedure (LEEP)
among those who are screen positive (ie, includes true and
false positives); Cured refers to the number of women who
were cured from a cervical intraepithelial neoplasia (CIN)
lesion among those who were treated and had screened
true positive. (C) Average number of screening tests, and
Cryo and LEEP treatments administered per year in phase
I (2020–2022) and phase II (2023–2040). Cryo, cryotherapy;
HPV, human papillomavirus; ICC, invasive cervical cancer;
VIA, visual inspection with acetic acid.

The better health outcomes under the adoption of
enhanced technologies will be the result of a substantial
strengthening in care engagement. That is, treatment
and true cure rates would be of 97.8% (5.13 million) and
62.7% (0.32 million), respectively (figure 3B). Neither
health gains nor care engagement would be substantially
improved by increasing target programmatic coverage
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Impact of CC screening and treatment options
The model predicts that scaling up any of the CC
screening and treatment options would achieve substantial improvements in health outcomes (figure 2). VIA-
Cryo only, VIA-
Cryo plus LEEP and HPV-
DNA-
Cryo
plus LEEP are expected to perform similarly, averting
approximately 32.6% (28 000) of CC cases and 23.9%
(10 702) of CC deaths by 2040, compared with status quo
(figure 2A,B - and supplementary table S3). As a result,
these three options would achieve a reduction in the age-
standardised incidence of CC to 143 per 100 000 women-
years by 2035–2039 (figure 2C - and supplementary table
S3).
In contrast to the above, scaling up an option with
enhanced technologies (ie, same-
day HPV-
DNA test
or digitally enhanced VIA) could reduce CC cases and
deaths by 50.2% (43 200) and 34.9% (15 612), respectively (figure 2A,B - and supplementary table S3). The
age-standardised incidence of CC would in turn reduce
to 99 per 100 000 women-years by 2035–2039 (figure 2C
- and supplementary table S3).
A number of factors explain the similar performance
of the three options without enhanced technologies. On
the one hand, LEEP availability will likely have its highest
impact during phase I, when a higher proportion of individuals will present with Cryo-ineligible lesions. Yearly
rescreening during later years (phase II) will allow for
earlier detection of lesions at Cryo-eligible stages, thus
reducing the need for LEEP (9.4% Cryo-ineligible lesions
in phase I vs 1.0% in phase II). On the other hand, there
will be a trade-off between the higher sensitivity of HPV-
DNA testing and lower proportion of LTFU associated
day VIA-
based options (figure 3A). Of all
with same-
individual screening events over the 20-year period, an
average of 35.8% (3.45 million) will be positive with VIA,
compared with 50.2% (4.81 million) with an HPV-DNA
test (figure 3B - and supplementary table S4). Despite the
higher sensitivity of the latter, only 73.5% (3.54 million)
of all of those with screen-positive results will receive
treatment in the HPV-DNA-Cryo plus LEEP option (due
to LTFU), compared with >97.9% (3.41 million) in both
VIA-based options (figure 3A - and supplementary table
S4). Moreover, the absolute cure rate (proportion cured
among those treated with an actual precancerous lesion)
will show a similar trend at 47.9% (0.22 million) compared
with 59.1% (0.21 million), respectively (figure 3B - and
supplementary table S4).
The trade-off between LTFU and test’s sensitivity will
be seen across the whole spectrum of possible scenarios.
For example, if sensitivity of VIA drops to 40% (ie, lowest
dependent nature)
reported values, given its operator-
while maintaining LTFU at 0%, only 21.0% (18 084) of
CC cases will be averted. Conversely, if the sensitivity of
HPV-DNA testing decreases to 75% (ie, lower bound of
reported CIs in the literature) at the same time its LTFU
decreases from 25% to 10%, the proportion of CC cases
averted will still be higher than baseline at 38.9% (33
499).
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Discussion
Our results show that any of the CC screening and treatment options recommended in Kenya for WHIV would
level health gains.
translate to substantial population-
Despite the better diagnostic performance of HPV-DNA
testing, its use will not result in superior health gains
compared with the efficient use of VIA, unless LTFU is
substantially minimised and, thus, engagement in care
ensured. The adoption of enhanced CC screening technologies, such as same-day HPV-DNA testing or digitally
enhanced VIA, could further improve health outcomes
and care engagement. Our model also highlights that
comprehensive treatment capabilities, including immediate access to Cryo and a widespread availability of facilities with LEEP capabilities, will be important to ensure
maximal health benefits from the initial phases of service
scale-up. As Kenya and other countries in the SSA region
scale up CC screening and treatment services, there will

be a need to be sensitive to health system constraints and
not dismiss pragmatic options at the cost of preventable
CC-related morbidity and mortality.
Our results are in line with previous evidence suggesting
that integrated CC screening and treatment services into
HIV care can be life-saving and that the added benefits of HPV-DNA tests, compared with VIA, depend on
ensuring LTFU is minimised.26 27 These and our results
highlight key implications for health systems of SSA that,
like Kenya, are looking to scale up CC screening coverage
and respond to the WHO’s call to eliminate CC.
First, a significant and immediate decrease in the
number of CC cases and deaths is possible with the
scale-up of any option of services, especially while waiting
for HPV vaccination to confer population-level protection. The availability of and capacity to provide CC
screening and treatment services in SSA will differ by
region and over time. Even in settings where resource
constraints hinder the use HPV-DNA testing, the efficient
use of VIA and Cryo only could yield significant reductions in the incidence and mortality of CC at the population level. The latter, however, must be contextualised
as a mean to scale up service delivery to be subsequently
leveraged on to provide same-day HPV-DNA testing and/
or digitally enhanced VIA.
Second, while adopting HPV-DNA tests as the primary
screening method is desirable to maximise individual and
population-level health outcomes, phasing in this technology will require strengthening service delivery platforms to ensure treatment with minimal LTFU. This is still
not universally possible, either because of recommendations of two-step approaches (triage of HPV-DNA-positive
women with VIA or cytology, which significantly decreases
its diagnostic sensitivity) or resource constraints.6 28
Nevertheless, transitioning to point-of-care, screen-and-
treat HPV-
DNA testing or digitally enhanced VIA has
been shown to be possible in SSA after establishing basic
infrastructure and human resources (eg, to provide VIA
and Cryo).29–33 This can be particularly feasible in HIV
care facilities, as WHIV represent a population regularly accessing healthcare. Notably, digitally enhanced
VIA warrants further evaluation before it can be recommended as a screening technology with similar performance to HPV-DNA testing. While mobile phone-based
technologies are in development, which could facilitate
its widespread adoption in resource-constrained settings,
their evaluation outside trial conditions is still needed.33
Third, the availability of LEEP would be particularly
important during the early stages of CC screening and
treatment service scale-up. Its delivery requires specialised infrastructure to address potential complications,
such as severe haemorrhages, which forestalls its availability in primary care facilities. Scale-up programmes in
SSA have successfully expanded LEEP services by leveraging on provincial facilities.32 Moreover, the successful
expansion of infrastructure to safely provide LEEP within
low-resource HIV care facilities has been demonstrated.9
Achieving this at a national scale in Kenya, while limiting
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beyond 70%. Moreover, health outcomes would not be
undermined by spacing out the frequency of rescreening
from yearly to three yearly (online supplementary material - table S5 and S6).
The scale-
up of any of the options will have an
important impact on the health system in terms of diagnostic and treatment resources needed. Approximately
9.6 million tests (either VIA or DNA) and 3.5 million
treatments (either Cryo or LEEP) would be needed
during the 20-year period with either of the three options
that do not use enhanced technologies. To target 70%
of WHIV at least once during phase I of either of these
three options the health system will have to provide an
average of 307 000 screening tests, 112 000 Cryo treatments and, for the case of VIA-Cryo plus LEEP and HPV-
DNA-Cryo plus LEEP, 11 700 LEEP treatments per year.
These annual requirements would need to be scaled up
in phase II in order to maintain rescreening and coverage
targets. The proportional increase would be of approximately 155% (average of 483 000) and 154% (average of
171 000 per year) for the case of screening tests and Cryo
treatments (figure 3C). However, LEEP requirements
would decrease by 86% (approximately 1600 per year—
figure 3C), as individuals with precancerous lesions are
increasingly diagnosed at earlier, Cryo-
eligible stages
during phase II.
The average number of yearly tests administered
with the use of enhanced technologies would need to
increase by approximately 163% (from 320 000 per year
in phase I to 530 000 in phase II), given the aforementioned optimised care engagement (figure 3B). Similarly,
the number of Cryo treatments would increase by 165%
(from 154 000 to 253 000 per year), and the number of
LEEP treatments would decrease by 89% (from 16 000
to 3000) (figure 3C). This intensive need for resources
could be decreased by spacing out the frequency of
rescreening in phase II from yearly to three yearly (online
supplementary material).
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the impact of the simulated CC screening and treatment strategies. However, the comparative impact of
the different options modelled would not differ. These
assumptions were based on most recent evidence in the
field,3 4 17 and the model performed well when compared
with HIV-specific epidemiological data from Kenya on
various stages of cervical disease (online supplementary
material). Second, the model assumed that HPV epidemiological data mainly collected from urban populations
in Kenya were applicable to the whole country. While this
may result in a different crude national-level burden of
HPV-related cervical disease among WHIV (depending
on urban/rural risk distribution), the proportion and
directionality of our results are unlikely to change.
Prospectively collected data, disaggregated by region and
HIV status, will be key for better parameterising future
modelling analyses. Third, no data are available from
Kenya regarding population-level CC mortality rates and
we thus fitted the model against available estimates for
the country from The Global Burden of Disease and
Globocan.37 38 This approach inherently introduces
external assumptions embedded in the modelling estimates from these two sources. Any estimation of CC
deaths will, as a result, be an overestimation or underestimation of the true population-level mortality. However, in
our mortality fit we ensured no assumptions on changes
to future trends of CC mortality were made, aiming to
represent what would be seen under status quo. Data from
nationally representative cancer registries are necessary
to better inform future analyses. Finally, the model did
not account for any vaccination-related immunity against
HPV in the population. While a national campaign
to vaccinate school-aged girls has been announced in
Kenya, there are no estimates of coverage rates in the
country.39 If a national-level HPV vaccination campaign,
with a catch-
up component for girls older than 15
years, was to be rolled out in the near future, the role
of CC screening and treatment in preventing morbidity
and mortality would be lessened over time. However,
if such vaccination catch-up component is not implemented, population-level protection would be delayed
for decades.40 Moreover, until nationwide vaccination
programmes are fully implemented, screening and treatment of precancerous cervical lesion remains the best
option to avert CC. Importantly, while immunogenicity
studies suggest WHIV achieve protection levels against
HPV strains similar to those of HIV-negative women,41
long-term prospective studies to assess clinical outcomes
among vaccinated adolescent WHIV are missing.
Further research is needed to clarify the economic
implications of scaling up national preventative
programmes towards achieving the goal of CC elimination among both WHIV and HIV-
negative women.
No study has looked into the cost benefit and cost
equity of such CC preventative interventions, nor the
potential impact of increasing heard immunity against
HPV (ie, as a result of vaccination) on the efficiency of
screening programmes. Accurate data collection on cost
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LTFU, could improve health gains during the early stages
of service scale-up, when more women will present with
advanced cervical lesions. Expanding LEEP availability
will be an important factor to consider for screening
programmes targeting WHIV, as they remain a population at high risk of both residual and recurrent CIN 2+
cervical disease,34 and thus may need repeated screening
and treatment with LEEP to minimise this risk.
Lastly, given expected population growth in SSA in the
upcoming decades, resource needs of any CC screening
programme will substantially increase over time. Health
systems will need to plan for a large upfront investment in
human resources and availability of commodities to reach
a target coverage of 70% and rescreening frequency. Our
model suggests this could be lessened by spacing out
the frequency of rescreening recommendations to three
yearly, in line with global recommendations,35 without
repercussions on population-level health gains. Top-level
discussions around the optimal frequency of rescreening
towards achieving this goal must be informed by prospective programmatic evidence, with disaggregation by age
and HIV status. Thus, any scale-up must be accompanied
by a robust monitoring and evaluation framework that
can effectively track programme performance.
To our knowledge, this is the first time a modelling
study evaluates potential population-level impact of CC
screening and treatment interventions by recreating
the entire population of interest, including their demographic structure, their age and HIV-specific risk of HPV
disease progression and ART initiation currently and over
time. Moreover, this is the first study to assess the scale-up
of a country’s CC screening and treatment guidelines
and identify how intervention factors (eg, availability of
specific technologies, diagnostic performance, LTFU)
can affect programmatic success. Our analyses highlight
that a phased scale-up of CC screening and treatment
services for WHIV in Kenya will be crucial to achieve the
2030 benchmarks set by the WHO towards CC elimination.5 We believe these results are applicable to other
high-HIV burden countries and the directionality of the
results to be applicable to HIV-
negative populations.
Previous models of CC among WHIV in SSA have focused
on cohort approaches to produce key contributions to
the cost-effectiveness literature of CC screening strategies.26 27 36 However, population-level health outcomes
have not been at the core of these studies, and simulated
strategies have been outside of those recommended
by national guidelines (eg, once in a lifetime) and/or
targeted idealised cohorts (where infection with HIV and
treatment with ART happens statically at an early age).
Several limitations to our modelling analyses must
be acknowledged. First, the model made a simplified
assumption that WHIV on ART for ≥2 years had the
same natural history of HPV-
related disease as HIV-
negative women, and ART adherence and failure were
not explicitly modelled. Our assumptions may result in
an overestimation of the protective effect of ART against
HPV-related cervical disease and therefore underestimate

BMJ Global Health

Author affiliations
1
Department of Infectious Disease Epidemiology, Imperial College London, London,
UK
2
Department of Medicine, Aga Khan University, Nairobi, Kenya
3
Global Health, University of Washington, Seattle, Washington, USA
4
Infections and Cancer Epidemiology Group, International Agency for Research on
Cancer, Lyon, France
5
Department of HIV/AIDS, World Health Organization, Geneva, Switzerland
6
National AIDS Control Council, Nairobi, Kenya
7
National AIDS and STI Control Programme, Nairobi, Kenya
8
Division of Infectious Diseases, University Hospitals Geneva, Geneva, Switzerland
Acknowledgements The authors thank the funders for supporting this work
as well as all national stakeholders who have supported the work by giving
guidance on scope, data and interpretation. The authors acknowledge the joint
centre funding from the UK Medical Research Council and the Department for
International Development.
Contributors PNPG, MS and TBH conceived the study. MS and PNPG adapted
the demographic and HIV parameters of the main individual-based model to
Kenya. PNPG developed the HPV natural history model, adapted it to Kenya and
carried out all modelling and statistical analyses. MS and TBH supervised all

analyses and secured funding for the work. MHC provided epidemiological data
for the prevalence of CIN 2/3 among WHIV. MHC, HDV, SD, KKM, BK and KM
contributed to the conceptual development of the options and the contextualisation
of the discussion in the Kenyan and SSA setting. PNPG did the first draft of this
manuscript. All authors extensively reviewed and contributed equally to the drafting
of the final version of this manuscript. The corresponding author had full access to
all the data in the study and had final responsibility for the decision to submit for
publication.
Funding This study was funded by CDRF Global, MRC Centre for Global Infectious
Diseases Analysis, and Foundation for the National Institutes of Health.
Disclaimer The funders of the study had no role in study design, data collection,
data analysis, data interpretation or writing of the report.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in
the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon request. Access to the
mathematical model code and all outputs used to calculate outcomes of the
present study can be granted upon request.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the
use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
ORCID iD
Pablo Noel Perez-Guzman http://orcid.org/0000-0002-5277-5196

References

1 Serrano B, Brotons M, Bosch FX, et al. Epidemiology and burden
of HPV-related disease. Best Pract Res Clin Obstet Gynaecol
2018;47:14–26.
2 Campos NG, Tsu V, Jeronimo J, et al. When and how often to screen
for cervical cancer in three low- and middle-income countries: a
cost-effectiveness analysis. Papillomavirus Res 2015;1:38–58.
3 Liu G, Sharma M, Tan N, et al. HIV-positive women have higher
risk of human papilloma virus infection, precancerous lesions, and
cervical cancer. AIDS 2018;32:795–808.
4 Looker KJ, Rönn MM, Brock PM, et al. Evidence of synergistic
relationships between HIV and human papillomavirus (HPV):
systematic reviews and meta-analyses of longitudinal studies of HPV
acquisition and clearance by HIV status, and of HIV acquisition by
HPV status. J Int AIDS Soc 2018;21:e25110.
5 World Health Organization. Cervical cancer elimination strategy,
2019. Available: https://www.who.int/cancer/cervical-cancer/
cervical-cancer-elimination-strategy [Accessed 5 Aug 2019].
6 Ministry of Health, Kenya.. Kenya National cancer screening
guidelines. Nairobi, 2018.
7 Ministry of Health, Kenya. Guidelines on use of antiretroviral drugs
for treating and preventing HIV in Kenya, 2018. Available: http://
cquin.icap.columbia.edu/wp-content/uploads/2017/04/ICAP_
CQUIN_Kenya-ARV-Guidelines-2018-Final_20thAug2018.pdf
[Accessed 29 Aug 2019].
8 Ng'ang'a A, Nyangasi M, Nkonge NG, et al. Predictors of cervical
cancer screening among Kenyan women: results of a nested case-
control study in a nationally representative survey. BMC Public
Health 2018;18:1221.
9 Khozaim K, Orang'o E, Christoffersen-Deb A, et al. Successes and
challenges of establishing a cervical cancer screening and treatment
program in Western Kenya. Int J Gynaecol Obstet 2014;124:12–18.
10 Orang'o EO, Wachira J, Asirwa FC, et al. Factors associated with
uptake of visual inspection with acetic acid (via) for cervical cancer
screening in Western Kenya. PLoS One 2016;11:e0157217.
11 Smit M, Olney J, Ford NP, et al. The growing burden of
noncommunicable disease among persons living with HIV in
Zimbabwe. AIDS 2018;32:773–82.
12 Smit M, Perez-Guzman PN, Mutai KK, et al. Mapping the current
and future noncommunicable disease burden in Kenya by human
immunodeficiency virus status: a modeling study. Clin Infect Dis
2019;11.

Perez-Guzman PN, et al. BMJ Global Health 2020;5:e001886. doi:10.1136/bmjgh-2019-001886

9

BMJ Glob Health: first published as 10.1136/bmjgh-2019-001886 on 29 March 2020. Downloaded from http://gh.bmj.com/ on January 6, 2021 by guest. Protected by copyright.

elements and the above analyses would be key to inform
relevant policy and funding discussions in the coming
years, as countries gear up to scale up CC preventative
efforts. There is also an evidence gap of large-scale trials
comparing cervical disease outcomes between Cryo ablation for women with an HPV-DNA-positive test without
versus already with cervical lesions. Current evidence
shows the former approach can lead to higher cervical
disease-free (CIN 2+) rates.35 42
Kenyan recommendations for HPV-
DNA testing as
the primary screening method for WHIV and the WHO
call to eliminate CC are ambitious. As health systems in
Kenya and the wider SSA region work to scale up CC
preventative services, different options of screening
and treatment technologies are at their disposal. The
emphasis, however, needs to remain on providing downstream treatment for those positively diagnosed in order
to avert CC cases and deaths. Our analyses show that
either of these options will have a positive impact on
the health of WHIV in care, but potential challenges to
their implementation must be critically assessed by policymakers and programme managers. Beyond opting for
better performing technologies, it will be the quality of
implementation of CC screening and treatment scale-up
that will drive programmatic success. Health systems
choosing to scale up HPV-DNA testing will need to do
so hand in hand with concerted efforts to minimise
LTFU. Conversely, those choosing to scale up VIA will
need to emphasise continuous provider training and
technological improvements to maximise its diagnostic
performance. Additionally, comprehensive treatment
capabilities, including immediate access to Cryo and a
widespread availability of referral facilities to perform
LEEP, will be key to maximise health outcomes from the
initial phases of service scale-up. Foremost, health systems
in SSA must aim for an early and sustainable engagement
of patients in CC screening and treatment services by
efficiently employing currently available technologies,
thereby effectively reducing CC morbidity and mortality.

BMJ Global Health

10

29
30

31
32

33
34

35

36

37
38
39
40
41
42
43

cervical cancer screening methods among HIV-positive women by
immune status and antiretroviral therapy. AIDS 2013;27:2909–19.
Murenzi G, Dusingize J-C, Rurangwa T, et al. Protocol for the study
of cervical cancer screening technologies in HIV-infected women
living in Rwanda. BMJ Open 2018;8:e020432.
Viviano M, DeBeaudrap P, Tebeu P-M, et al. A review of screening
strategies for cervical cancer in human immunodeficiency virus-
positive women in sub-Saharan Africa. Int J Womens Health
2017;9:69–79.
Umulisa MC, Franceschi S, Baussano I, et al. Evaluation of human-
papillomavirus testing and visual inspection for cervical cancer
screening in Rwanda. BMC Womens Health 2018;18:59.
Parham GP, Mwanahamuntu MH, Kapambwe S, et al. Population-
level scale-up of cervical cancer prevention services in a low-
resource setting: development, implementation, and evaluation
of the cervical cancer prevention program in Zambia. PLoS One
2015;10:e0122169.
Urner E, Delavy M, Catarino R, et al. A smartphone-based approach
for triage of human papillomavirus-positive sub-Saharan African
women: a prospective study. JMIR Mhealth Uhealth 2017;5:e72.
Debeaudrap P, Sobngwi J, Tebeu P-M, et al. Residual or recurrent
precancerous lesions after treatment of cervical lesions in
human immunodeficiency virus-infected women: a systematic
review and meta-analysis of treatment failure. Clin Infect Dis
2019;69:1555–65.
Santesso N, Mustafa RA, Schünemann HJ, et al. World Health
organization guidelines for treatment of cervical intraepithelial
neoplasia 2-3 and screen-and-treat strategies to prevent cervical
cancer. Int J Gynaecol Obstet 2016;132:252–8.
Atashili J, Smith JS, Adimora AA, et al. Potential impact of
antiretroviral therapy and screening on cervical cancer mortality in
HIV-positive women in sub-Saharan Africa: a simulation. PLoS One
2011;6:e18527.
Institute for Health Metrics and Evaluations. GBD compare. Institute
for Health Metrics and Evaluation, 2014. http://www.healthdata.org/
data-visualization/gbd-compare
Globocan. Cancer tomorrow. Available: http://gco.iarc.fr/tomorrow/
home [Accessed 13 Nov 2019].
Bruni L, Albero G, Serrano B, et al. Human papillomavirus and
related diseases report in Kenya, 2019. Available: https://hpvcentre.
net/statistics/reports/KEN.pdf [Accessed 2 Aug 2019].
Jit M, Brisson M, Portnoy A, et al. Cost-effectiveness of female
human papillomavirus vaccination in 179 countries: a PRIME
modelling study. Lancet Glob Health 2014;2:e406–14.
Lacey CJ. HPV vaccination in HIV infection. Papillomavirus Res
2019;8:100174.
Franceschi S. Past and future of prophylactic ablation of the cervical
squamocolumnar junction. Ecancermedicalscience 2015;9:527.
Pfaendler KS, Mwanahamuntu MH, Sahasrabuddhe VV, et al.
Management of cryotherapy-ineligible women in a "screen-
and-treat" cervical cancer prevention program targeting HIV-
infected women in Zambia: lessons from the field. Gynecol Oncol
2008;110:402–7.

Perez-Guzman PN, et al. BMJ Global Health 2020;5:e001886. doi:10.1136/bmjgh-2019-001886

BMJ Glob Health: first published as 10.1136/bmjgh-2019-001886 on 29 March 2020. Downloaded from http://gh.bmj.com/ on January 6, 2021 by guest. Protected by copyright.

13 United Nations. World population prospects, 2019. Available: https://
population.un.org/wpp/Graphs/Probabilistic/404 [Accessed 5 Aug
2019].
14 AIDSinfo, UNAIDS. Available: http://aidsinfo.unaids.org/ [Accessed 5
Aug 2019].
15 Mangal TD, UNAIDS Working Group on CD4 Progression and
Mortality Amongst HIV Seroconverters including the CASCADE
Collaboration in EuroCoord. Joint estimation of CD4+ cell
progression and survival in untreated individuals with HIV-1 infection.
AIDS 2017;31:1073–82.
16 Smit M, Perez-Guzman PN, Mutai KK, et al. Mapping the current and
future non-communicable disease burden in Kenya by HIV status:
a modelling study. Clin Infect Dis 2019. doi:10.1093/cid/ciz1103.
[Epub ahead of print: 17 Nov 2019].
17 Kelly H, Weiss HA, Benavente Y, et al. Association of antiretroviral
therapy with high-risk human papillomavirus, cervical intraepithelial
neoplasia, and invasive cervical cancer in women living with HIV: a
systematic review and meta-analysis. Lancet HIV 2018;5:e45–58.
18 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. BMJ
2009;339:b2535.
19 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of
observational studies in epidemiology: a proposal for reporting.
Meta-analysis of observational studies in epidemiology (moose)
group. JAMA 2000;283:2008–12.
20 Greene SA, De Vuyst H, John-Stewart GC, et al. Effect of
cryotherapy vs loop Electrosurgical excision procedure on cervical
disease recurrence among women with HIV and high-grade cervical
lesions in Kenya: a randomized clinical trial. JAMA 2019;322:1570–9.
21 Greene SA, Topazian H, De Vuyst H. LEEP treatment of extensive
cervical intraepithelial neoplasia in HIV-infected women. Boston;
2018: A658.
22 Sudenga SL, Rositch AF, Otieno WA, et al. Knowledge, attitudes,
practices, and perceived risk of cervical cancer among Kenyan
women: brief report. Int J Gynecol Cancer 2013;23:895–9.
23 Rosser JI, Njoroge B, Huchko MJ. Knowledge about cervical cancer
screening and perception of risk among women attending outpatient
clinics in rural Kenya. Int J Gynaecol Obstet 2015;128:211–5.
24 Ahmad OB, Boschi-Pinto C, Lopez AD, et al. Age standardization of
rates: a new who standard;14.
25 Monks T, Currie CSM, Onggo BS, et al. Strengthening the reporting
of empirical simulation studies: introducing the stress guidelines. J
Simul 2019;13:55–67.
26 Zimmermann MR, Vodicka E, Babigumira JB, et al. Cost-
effectiveness of cervical cancer screening and preventative
cryotherapy at an HIV treatment clinic in Kenya. Cost Eff Resour
Alloc 2017;15:13.
27 Campos NG, Lince-Deroche N, Chibwesha CJ, et al. Cost-
effectiveness of cervical cancer screening in women living with HIV
in South Africa: a mathematical modeling study. J Acquir Immune
Defic Syndr 2018;79:195–205.
28 Chung MH, McKenzie KP, De Vuyst H, et al. Comparing Papanicolau
smear, visual inspection with acetic acid and human papillomavirus

